All In Biotech

Drug Trial Radar · NCT06451159

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jun 20, 2024

Primary completion

Feb 1, 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Bruce CreeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kyverna Therapeutics
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.

Conditions

  • Progressive Multiple Sclerosis

Interventions

  • KYV-101 (Biological) - 0.33 ×10^8 cellsBiological

    KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.

  • KYV-101 (Biological) - 1 ×10^8 cellsBiological

    KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.

  • Chemotherapy: cyclophosphamide (CYC)Drug

    Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.

  • Chemotherapy: fludarabine (FLU)Drug

    Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The presence of CAR-T cells in CSF following their peak expansion in peripheral blood.Time frame: Screening to Week 48
  2. The incidence and severity of adverse events and dose-limiting toxicities.Time frame: Screening to Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco, Multiple Sclerosis Center

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.